Abstract: An image processing device according to the present technology includes: a foreground-background classification unit configured to classify an input image into a foreground image portion which is a portion in which a subject in a foreground is captured and a background image portion which is a portion in which a subject in a background farther than the foreground image portion is captured; a foreground correction unit configured to correct the foreground image portion; and an inconsistency correction unit configured to correct an inconsistent portion caused by the correction of the foreground image portion by the foreground correction unit.

Abstract: The polycarbonate resin composition according to the present invention includes: 50 to 90% by mass of polycarbonate resin (A); 2.0 to 20% by mass of olefin polymer (B); 5 to 40% by mass of basic magnesium sulfate (C) selected from fibrous basic magnesium sulfate (C-1) and fan-shaped basic magnesium sulfate (C-2); 0.1 to 8% by mass of at least one (D) selected from a fatty acid metal salt and a fatty acid; and 1 to 20% by mass of elastomer (E).

Abstract: The degradation promoter for an aliphatic polyester biodegradable resin according to the present invention contains basic magnesium sulfate.

Abstract: The biodegradable resin composition according to the present invention contains an aliphatic polyester biodegradable resin and fibrous basic magnesium sulfate.

Abstract: A polycarbonate resin composition includes: 50 to 90% by mass of polycarbonate resin (A); 2 to 30% by mass of acrylonitrile-butadiene-styrene copolymer resin (B); 5 to 40% by mass of at least one basic magnesium sulfate (C) selected from fibrous basic magnesium sulfate (C-1) and fan-shaped basic magnesium sulfate (C-2); 0.1 to 8% by mass of at least one (D) selected from a fatty acid metal salt and a fatty acid; and 1 to 20% by mass of elastomer (E).

Abstract: The polycarbonate resin composition according to the present invention includes: 50 to 90% by mass of polycarbonate resin (A); 2.0 to 20% by mass of olefin polymer (B); 5 to 40% by mass of basic magnesium sulfate (C) selected from fibrous basic magnesium sulfate (C-1) and fan-shaped basic magnesium sulfate (C-2); 0.1 to 8% by mass of at least one (D) selected from a fatty acid metal salt and a fatty acid; and 1 to 20% by mass of elastomer (E).

Abstract: A filler composition comprising fibrous basic magnesium sulfate particles and non-fibrous inorganic micro-particles having an average particle diameter in the range of 0.001 to 0.5 ?m in a ratio by weight in the range of 100:0.001 to 100:50, and a polyolefin resin composition comprising a polyolefin resin, fibrous basic magnesium sulfate particles and non-fibrous inorganic micro-particles having an average particle diameter in the range of 0.001 to 0.5 ?m, in which the polyolefin resin and fibrous basic magnesium sulfate particles are present in a weight ratio of 99:1 to 50:50, and the non-fibrous inorganic micro-particles are present in an amount of 0.001 to 50 weight parts per 100 weight parts of the basic fibrous magnesium sulfate particles and/or in an amount of 0.0002 to 10 weight parts, per 100 weight parts of the resin.

Abstract: An object of the present invention is to provide a PC/ABS-based thermoplastic resin composition and a molded article thereof excellent in impact resistance. A thermoplastic resin composition comprising: a polycarbonate (A); at least one resin (B) selected from the group consisting of an ABS resin, an ASA resin, an AES resin and a SAN resin; an unsaturated dicarboxylic acid anhydride-based copolymer (C); and an additive (D), wherein the additive (D) has a function promoting hydrolysis of polycarbonate, and with a content of (C) is 2 to 25 parts by mass.

Abstract: An object of the present invention is to provide a PC/ABS-based thermoplastic resin composition and a molded article thereof excellent in impact resistance. A thermoplastic resin composition comprising: a polycarbonate (A); at least one resin (B) selected from the group consisting of an ABS resin, an ASA resin, an AES resin and a SAN resin; an unsaturated dicarboxylic acid anhydride-based copolymer (C); and an additive (D), wherein the additive (D) has a function promoting hydrolysis of polycarbonate, and with a content of (C) is 2 to 25 parts by mass.

Abstract: A filler composition comprising fibrous basic magnesium sulfate particles and non-fibrous inorganic micro-particles having an average particle diameter in the range of 0.001 to 0.5 ?m in a ratio by weight in the range of 100:0.001 to 100:50, and a polyolefin resin composition comprising a polyolefin resin, fibrous basic magnesium sulfate particles and non-fibrous inorganic micro-particles having an average particle diameter in the range of 0.001 to 0.5 ?m, in which the polyolefin resin and fibrous basic magnesium sulfate particles are present in a weight ratio of 99:1 to 50:50, and the non-fibrous inorganic micro-particles are present in an amount of 0.001 to 50 weight parts per 100 weight parts of the basic fibrous magnesium sulfate particles and/or in an amount of 0.0002 to 10 weight parts, per 100 weight parts of the resin.

Abstract: Provided are a polycarbonate/ABS-based thermoplastic resin composition excellent in hydrolysis resistance and impact resistance and a molded article thereof. A thermoplastic resin composition includes: polycarbonate (A); a graft copolymer (B) produced by graft copolymerization of a rubbery polymer at least with a styrene-based monomer and an acrylonitrile-based monomer and containing a metal element; a styrene-acrylonitrile based copolymer (C); and an unsaturated dicarboxylic anhydride-based copolymer (D), wherein a content of (D) is 2 to 25 mass %.

Abstract: There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I?): (in the above-mentioned general formula (I?), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.

Abstract: Provided are novel compounds that bind to FKBP12 or pharmaceutically acceptable salts thereof, as well as new therapeutics useful in the prevention or treatment of alopecia which comprise those compounds or pharmaceutically acceptable salts thereof. Specifically, compounds represented by formula (1) [where R1 represents either the following formula (2) or (3)] or pharmaceutically acceptable salts thereof are provided.

Abstract: There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I?): (in the above-mentioned general formula (I?), W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof.

Abstract: Provided are novel compounds that bind to FKBP12 or pharmaceutically acceptable salts thereof, as well as new therapeutics useful in the prevention or treatment of alopecia which comprise those compounds or pharmaceutically acceptable salts thereof. Specifically, compounds represented by formula (1) [where R1 represents either the following formula (2) or (3)] or pharmaceutically acceptable salts thereof are provided.

Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.

Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a pharmaceutical.

Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.

Abstract: An object of the present invention is to provide a compound having an action of inhibiting binding between S1P and its receptor, Edg-1 (S1P1), and is useful as a pharmaceutical compound. A compound or a pharmaceutically acceptable salt thereof, which compound is represented by the formula below (where A represents an oxygen atom, a sulfur atom, a group represented by Formula —SO—, a group represented by Formula —SO2—, or the like, R1 represents a hydrogen atom, an alkyl group having 1-6 carbon atoms, or the like, R1A represents a hydrogen atom or the like, R2 represents an alkyl group having 1-6 carbon atoms, a cycloalkyl group having 3-6 carbon atoms, or the like, R3 represents an aryl group, R4 represents a hydrogen atom or an alkyl group having 1-6 carbon atoms and optionally substituted with a carboxyl group, and R5 represents an alkyl group having 1-10 carbon atoms, a cycloalkyl group having 3-8 carbon atoms, an aryl group which is optionally substituted, or the like).

Abstract: An object of the present invention is to provide a compound having an action of inhibiting binding between S1P and its receptor, Edg-1 (S1P1), and is useful as a pharmaceutical compound. A compound or a pharmaceutically acceptable salt thereof, which compound is represented by the formula below (where A represents an oxygen atom, a sulfur atom, a group represented by Formula —SO—, a group represented by Formula —SO2—, or the like, R1 represents a hydrogen atom, an alkyl group having 1-6 carbon atoms, or the like, R1A represents a hydrogen atom or the like, R2 represents an alkyl group having 1-6 carbon atoms, a cycloalkyl group having 3-6 carbon atoms, or the like, R3 represents an aryl group, R4 represents a hydrogen atom or an alkyl group having 1-6 carbon atoms and optionally substituted with a carboxyl group, and R5 represents an alkyl group having 1-10 carbon atoms, a cycloalkyl group having 3-8 carbon atoms, an aryl group which is optionally substituted, or the like).